N-(2-Pyrazinylcarbonyl)-L-phenylalanine

Product Details

CAS No:114457-94-2

MF:C14H13N3O3

Appearance:white or off-white crystalline powder

Specification:98.5%

UN number:-

Package:1/5/10/25kgs/drum

Supply Capacity:Tons

Synonyms:(S)-3-PHENYL-2-[(PYRAZIN-2-YLCARBONYL)AMINO] PROPANOIC ACID;(S)-3-Phenyl-2-[(pyrazine-2-carbonyl)-amino]-propionic acid;Bortezomib Intermediate 2;N-Pyrazinylcarbonyl-L-phenylalanine;N-(2-Pyrazinylcarbonyl)-L-phenylalanine;Bortezomib Acid Impurity;Bortezomib INT B;N-(Pyrazinylcarbonyl)-L-phenylalanine

Product application:N-(2-Pyrazinylcarbonyl)-L-phenylalanine,114457-94-2,Pyrazine-2-carbonyl-L-phenylalanine,Bortezomib intermediate,Bortezomib key intermediate,N-(Pyrazine-2-carbonyl)-L-phenylalanine,(2S)-2-(Pyrazine-2-carboxamido)-3-phenylpropanoic acid,Antineoplastic intermediate,Proteasome inhibitor building block,Multiple myeloma API raw material,Mantle cell lymphoma drug intermediate,Chiral phenylalanine derivative,Peptidomimetic intermediate,High purity Bortezomib intermediate 99%,Pharmaceutical intermediate CAS 114457-94-2,API building block,Oncology drug synthesis reagent,Custom synthesis intermediate,CAS 114457-94-2 supplier,N-(2-Pyrazinylcarbonyl)-L-phenylalanine manufacturer China,Suzhou Health Chemicals pharma intermediates,Bortezomib intermediate wholesale bulk export

 

N-(2-Pyrazinylcarbonyl)-L-phenylalanine plays an essential and highly specialized role across the pharmaceutical oncology sector, commercial API manufacturing, and modern chemical biology research. Functioning as the vital peptide core intermediate for the commercial chemical synthesis of Bortezomib, a first-in-class proteasome inhibitor, it undergoes stereospecific coupling with chiral boronic acid derivatives to form therapeutic active ingredients approved globally for the clinical management of multiple myeloma and relapsed or refractory mantle cell lymphoma; in medicinal chemistry and innovative drug discovery, it is extensively utilized as a structural scaffold for engineering novel peptidomimetic proteasome modulators, ubiquitin-proteasome pathway targeting molecules, and dual-action oncology candidates designed to circumvent therapeutic drug resistance; furthermore, in fundamental biomedical research and cell biology, this compound serves as an invaluable functional building block and biochemical probe for investigating proteasomal degradation kinetics, tumor apoptosis signaling pathways, and cell-cycle regulatory mechanisms.